GlassScriptPhysician profile
Stacy I Ejem
NPI 1376993725
$5,038.63
in general payments reported to CMS, 2019-2025
36 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.74 · 2020: $130 · 2021: $96.39 · 2022: $459 · 2023: $1,845 · 2024: $843 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.42 |
| Education | $194.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $969.32 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $416.66 | 2022-2025 | Acthar |
| Amgen INC. | $382.63 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $352.86 | 2022-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $351.01 | 2023 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $350.30 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $273.35 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.27 | 2022-2025 | Ofev |
| Novo Nordisk INC | $218.23 | 2021-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $216.11 | 2023-2025 | Glassia |
| Genzyme Corporation | $145.56 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $143.17 | 2022-2025 | Zerbaxa, Dificid |
| Metuchen Pharmaceuticals | $130.44 | 2020 | |
| Melinta Therapeutics, LLC | $125.00 | 2022 | |
| Viatris Specialty LLC | $97.73 | 2025 | Yupelri |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $93.75 | 2023-2024 | Hizentra |
| Philips North America LLC | $65.78 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| United Therapeutics Corporation | $59.67 | 2022-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $55.18 | 2022-2024 | Smartvest |
| Pulmonx Corporation | $43.50 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Gilead Sciences, INC. | $33.93 | 2022-2023 | |
| Liquidia Technologies, INC. | $28.92 | 2025 | Yutrepia |
| Inspire Medical Systems, INC. | $24.22 | 2025 | Inspire |
| Vifor Pharma, INC. | $23.06 | 2024 | Zemaira |
| Harmony Biosciences LLC | $21.61 | 2024 | |
| Ethicon INC. | $20.96 | 2025 | Monarch Platform |
| Getinge USA Sales, LLC | $19.64 | 2024 | Cardiosave Hybrid, Type B Plug |
| Inogen, INC. | $19.64 | 2023 | Inogen At Home Stationary Concentrator |
| Axsome Therapeutics, INC. | $19.37 | 2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $18.98 | 2025 | Uptravi |
| Lilly USA, LLC | $18.01 | 2025 | Zepbound |
| Abbvie INC. | $17.26 | 2023 | |
| Mylan Specialty L.P. | $15.98 | 2023 | Yupelri |
| Pfizer INC. | $15.23 | 2022 | |
| Shionogi INC | $15.03 | 2023 | Fetroja |
| La Jolla Pharmaceutical Company | $14.27 | 2023 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Ejem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.